Abstract
To assess prescribing practices of noninsulin antidiabetic drugs (NIADs) in T2DM with several major contraindications according to prescribing information or clinical guidelines: renal failure, heart failure, liver dysfunction, or history of bladder cancer. Cross-sectional, descriptive, multicenter study. Electronic medical records were retrieved from all T2DM subjects who attended primary care centers pertaining to the Catalan Health Institute in Catalonia in 2013 and were pharmacologically treated with any NIAD alone or in combination. Records were retrieved from a total of 255,499 pharmacologically treated patients. 78% of patients with some degree of renal impairment (glomerular filtration rate (GFR) < 60 mL/min) were treated with metformin and 31.2% with sulfonylureas. Even in the event of severe renal failure (GFR < 30 mL/min), 35.3% and 22.5% of patients were on metformin or sulfonylureas, respectively. Moreover, metformin was prescribed to more than 60% of patients with moderate or severe heart failure. Some NIADs, and in particular metformin, were frequently used in patients at high risk of complications when they were contraindicated. There is a need to increase awareness of potential inappropriate prescribing and to ...Continue Reading
References
Sep 7, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·A HolsteinE H Egberts
Jul 27, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·A M Emslie-SmithUNKNOWN DARTS/MEMO Collaboration
Feb 28, 2002·Archives of Internal Medicine·Amy T CalabreseR Harsha Rao
Jun 22, 2002·The Cochrane Database of Systematic Reviews·S SalpeterE Salpeter
Jun 14, 2003·The Cochrane Database of Systematic Reviews·S SalpeterE Salpeter
Jul 3, 2003·JAMA : the Journal of the American Medical Association·Frederick A MasoudiHarlan M Krumholz
Jul 28, 2004·Diabetes Care·Gregory A NicholsJonathan B Brown
Sep 1, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·James McCormackHugh Tildesley
Mar 1, 2007·Diabetes Care·Keith G TolmanMeng H Tan
Sep 1, 2007·BMJ : British Medical Journal·Dean T EurichJeffrey A Johnson
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Aug 20, 2009·Current Diabetes Reviews·Linuo ZhouRenming Hu
Jan 30, 2010·Clinical Therapeutics·Carol E KoroSteve J Bowlin
May 27, 2010·Diabetes/metabolism Research and Reviews·Paolo PozzilliStefano Del Prato
Dec 25, 2010·Pharmacoepidemiology and Drug Safety·Yu-Wen WenPei-Fen Chen
Feb 22, 2012·Diabetes Care·Irene VinagreDidac Mauricio
Mar 1, 2012·Current Medical Research and Opinion·Shih-Yin ChenLuke Boulanger
Mar 27, 2012·Medicina clínica·Bonaventura BolíbarUNKNOWN Grupo SIDIAP
Apr 21, 2012·Diabetes Care·Silvio E InzucchiUNKNOWN European Association for the Study of Diabetes (EASD)
May 23, 2012·European Heart Journal·John J V McMurrayUNKNOWN ESC Committee for Practice Guidelines
Feb 14, 2013·Journal of Medical Economics·S Y ChenD Brixner
Mar 20, 2013·Circulation. Heart Failure·Dean T EurichFinlay A McAlister
Apr 12, 2013·Cardiovascular Diabetology·Diethelm TschöpePetra-Maria Schumm-Draeger
Nov 22, 2013·The Annals of Pharmacotherapy·Wenya R LuAmy Braun
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Sep 18, 2014·BMC Nephrology·Antonio Rodriguez-PoncelasXavier Mundet-Tuduri
Sep 28, 2014·BMC Cardiovascular Disorders·Cristina Varas-LorenzoSusana Perez-Gutthann
Dec 24, 2014·JAMA : the Journal of the American Medical Association·Silvio E InzucchiDarren K McGuire
Dec 30, 2014·Diabetes Care·Silvio E InzucchiDavid R Matthews
Citations
Aug 25, 2017·Clinical Drug Investigation·Weiyi HuangGregory M Peterson
Jun 29, 2017·Diabetes, Obesity & Metabolism·Manel Mata-CasesDídac Mauricio
Aug 20, 2020·JBI Evidence Synthesis·Mohammed B AyalewM Joy Spark
Feb 20, 2021·Primary Care Diabetes·Manel Mata-CasesDídac Mauricio